Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for neuromyelitis optica spectrum disorder (NMOSD). The move follows a recommendation ...

A Parkinson’s disease drug has been effective in reducing the symptoms of treatment-resistant depression. Led by the UK’s University of Oxford, the trial (ISRCTN84666271) found pramipexole to be ...

NKGen Biotech has activated two new trial sites in Canada and Florida, US, for the Phase I/IIa study of its cryopreserved expanded autologous natural killer (NK) cell therapy, troculeucel, in patients ...

According to the speaker, there are also advantages to Japan has a fast pricing and reimbursement process, with price negotiations running in parallel with new drug application (NDA) reviews. In the ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo ...

GlobalData polling finds that 57% of business professionals are ‘very concerned’ about the potential impact of tariffs on their business. [i] For pharma companies, navigating customs is already a ...

US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic dermatitis (AD). The INTEGUMENT-INFANT trial will ...

Arrowhead Pharmaceuticals has dosed the first participant in the Phase I/IIa AROALK7-1001 trial of ARO-ALK7, an investigational RNA interference (RNAi) therapeutic aimed at treating obesity. The trial ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC), has ...

Owen was speaking at a session on clinical trial decarbonisation at the 15th Annual Clinical Trial in Oncology West Coast (CTO) conference, which took place earlier this month. According to him, ...

Gilgamesh Pharmaceuticals’ psychedelic therapy has boasted a 94% depression remission rate after 29 days in a Phase IIa study. The trial (NCT06236880) investigated the efficacy, safety and durability ...

Prothena CEO and president Gene Kinney said: “This is not the outcome that we expected, and we are surprised and disappointed by these results for patients, their families and caregivers, and for the ...